ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2019

Conference call and webcast on Tuesday, March 17 at 1:30 pm CET/8:30 am ET

  • More than two-thirds of the expected number of patients have been enrolled in the TRYbeCA-1 Phase 3 clinical trial
  • Cash position of €73.2 million ($82.2 million) at the end of 2019
Menu